Medical debulking with BRAF/MEK inhibitors in aggressive
BRAF
-mutant craniopharyngioma
Neurooncol Adv
.
2020 Oct 15;2(1):vdaa141.
doi: 10.1093/noajnl/vdaa141.
eCollection 2020 Jan-Dec.
Authors
Anna Luisa Di Stefano
1
2
,
David Guyon
1
,
Karine Sejean
3
,
Loic Feuvret
4
5
,
Chiara Villa
6
,
Giulia Berzero
7
,
Virginie Desforges Bullet
8
,
Emmanuel Halimi
9
,
Anne Boulin
10
,
Bertrand Baussart
11
,
Stephan Gaillard
11
Affiliations
1
Department of Neurology, Hôpital Foch, Suresnes, France.
2
Inserm U 1127, CNRS UMR 7225, Sorbonne Université, UPMC Univ. Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, Paris, France.
3
Pharmacy Department, Hôpital Foch, Suresnes, France.
4
Department of Radiation Oncology, Hôpital La Pitié-Salpêtrière, Paris, France.
5
Department of Radiation Oncology, Institut Curie, Centre de protonthérapie d'Orsay, Orsay Cedex, France.
6
Department of Pathology, Hôpital Foch, Suresnes, France.
7
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
8
Service d'endocrinologie-diabétologie, centre hospitalier de Versailles, Le Chesnay, France.
9
Department of Ophtalmology, Hôpital Foch, Suresnes, France.
10
Department of Neuroradiology, Hôpital Foch, Suresnes, France.
11
Department of Neurosurgery, Hôpital Foch, Suresnes, France.
PMID:
33241217
PMCID:
PMC7680180
DOI:
10.1093/noajnl/vdaa141
No abstract available
Keywords:
BRAF V600E mutation; anti-BRAF; anti-MEK; papillary craniopharyngioma; target therapy.